Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Tolcapone

Claire Willman  1 , Prasanna Tadi  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Tolcapone

Claire Willman et al.
Free Books & Documents

Excerpt

Tolcapone is a medication used in the management and treatment of Parkinson disease. It is in the catechol-O-methyl transferase inhibitor class of drugs. This activity reviews the indications, action, and contraindications for tolcapone as a valuable agent in the management of Parkinson disease. This activity will highlight the mechanism of action, adverse event profile, off-label uses, and monitoring that is pertinent for members of the interprofessional team in the care of patients with Parkinson disease and related conditions.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Claire Willman declares no relevant financial relationships with ineligible companies.

Disclosure: Prasanna Tadi declares no relevant financial relationships with ineligible companies.

References

    1. Truong DD. Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging. 2009;4:109-13. - PMC - PubMed
    1. Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):421-8. - PMC - PubMed
    1. Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, LeWitt P, Chernik DA, Dorflinger EE, Yoo K. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology. 1997 Jan;48(1):81-7. - PubMed
    1. Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, Deptula D, Pedder S. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group. Neurology. 1998 May;50(5 Suppl 5):S39-45. - PubMed
    1. Pinheiro SD, Serrão MP, Silva T, Borges F, Soares-da-Silva P. Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors. Eur J Pharmacol. 2019 Mar 15;847:53-60. - PubMed

Publication types

LinkOut - more resources